Biohit Oyj - Decisions of general meeting

Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj April 8, 2013 at 5.45 P.M. local time



The Annual General Meeting (AGM) of Biohit Oyj held on Monday April 8, 2013
approved the financial statements of the parent company and the consolidated
financial statements, and discharged the members of the Board of Directors and
the President and CEO from liability for the financial year 2012. 


Distribution of dividends

In accordance with the proposal by the Board of Directors, the AGM decided that
the loss for the financial period ended on December 31, 2012 will be recorded
in the profit and loss account. 

In accordance with the proposal by the Board of Directors, the AGM decided that
on the basis of the financial statements for the financial period ended on
December 31, 2012, a dividend of EUR 0.4964 per each A share and EUR 0.4998 for
each B share be paid. Dividend will be paid to shareholders recorded in the
company's shareholder register on the matching day, April 11, 2013. Dividend
will be paid out on April 18, 2013. 

In accordance with the proposal of the Board of Directors, the AGM decided that
on the basis of the financial statements for the financial period ended on
December 31, 2012, funds from the invested non-restricted equity fund be
distributed to shareholders as a capital repayment, with the capital repaid
amounting to EUR 0.237 for each A and B share. Capital will be repaid to
shareholders recorded in the company's shareholder register on the repayment
day on April 11, 2013. Capital repayment will be made on April 18, 2013. 


Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be
five (5). Furthermore, that the following Board members re-elected until the
end of the next AGM:  Professor Osmo Suovaniemi, Professor Mikko Salaspuro,
Commercial Counselor Eero Lehti, M.Sc.Eng. Seppo Luode, and as a new board
member CEO Franco Aiolfi. 

Additionally, the AGM decided that the chairman of the Board of Directors would
be paid a monthly fee of EUR 1,600 and the ordinary members would be paid a
monthly fee of EUR 1,500. 


Auditors

The AGM elected authorised public accountants Ernst & Young Oy as the company's
auditors, with APA Erkka Talvinko as the head auditor, until the end of the
next AGM. 

All decisions of the AGM were made unanimously. The minutes of the AGM will be
available for review by shareholders by April 22, 2013 on the company's website
(www.biohithealthcare.com / investors) and at the corporate headquarters of
Biohit, located at Laippatie 1, 00880 Helsinki. 


Additional information:

CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealthcare.com



Biohit in brief

Biohit Oyj is a Finnish biotechnology company operating globally that was
established in 1988. Biohit's mission is "Innovating for Health". The purpose
of the company is to take social responsibility and produce innovation, new
technologies and analysis systems for use in medicine, research institutions
and industry, helping to promote research and diagnostics and to improve the
quality of life of people by means of preventing disease, human suffering and
financial loss. We are committed to social responsibility and it is our duty to
spread knowledge about the Group 1 human carcinogen, acetaldehyde, and innovate
and develop the marketing and availability of our products and services. Biohit
is headquartered in Helsinki and its subsidiaries are located in China and the
United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed
in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.